Use of glucagon‐like peptide‐1 receptor agonists in eating disorder populations

Abstract

AbstractGlucagon‐like peptide‐1 receptor agonists (GLP‐1As) are being used as approved or off‐label treatments for weight loss. As such, there has been increasing concern about the potential for GLP‐1As to impact eating disorder (ED) symptomatology. This article seeks to (1) review the current state of knowledge regarding GLP‐1As and ED symptomatology; (2) provide recommendations for future research; and (3) guide ED clinicians in how to discuss GLP‐1As in clinical practice. Although evidence is limited, it is possible that GLP‐1As could exacerbate, or contribute to the development of, ED pathology and negatively impact ED treatment. Preliminary research on the use of GLP‐1As to treat binge eating has been conducted; however, studies have design limitations and additional research is needed. Therefore, at the current time there is not sufficient evidence to support the use of GLP‐1s to treat ED symptoms. In summary, more research is required before negative or positive conclusions can be drawn about the impact of GLP‐1As on EDs psychopathology. Herein, we provide specific recommendations for future research and a guide to help clinicians navigate discussions with their clients about GLP‐1As. A client handout is also provided.Public SignificanceDespite glucagon‐like peptide‐1 receptor agonists (GLP‐1As; e.g., semaglutide) increasingly being the topic of clinical and public discourse, little is known about their potential impact on ED symptoms. It is possible that GLP‐1As could maintain, worsen, or improve ED symptoms. This article reviews the limited literature on GLP‐1As and ED symptoms, recommends future research, and provides clinicians with a guide for discussing GLP‐1As with ED clients.